Bruker publishes 2025 annual report, posts $3.44 billion revenue

Bruker Corporation

Bruker Corporation

BRKR

0.00
  • Bruker released its annual report for fiscal 2025, highlighting a transition year in its portfolio shift toward post-genomic workflow solutions.
  • Strategy emphasis moved to Project Accelerate 3.0, expanding into spatial biology, proteomics, clinical microbiology, molecular diagnostics, lab automation, software, and recurring revenue.
  • Integration of 2024 acquisitions remained central, with ELITech strengthening molecular diagnostics, Chemspeed expanding lab automation, NanoString anchoring spatial biology.
  • Product momentum included launches such as CosMx Whole Human Transcriptome, timsOmni-enabled Functional Proteomics 2.0 to reinforce positioning in disease biology research and drug discovery.
  • Management cited macro headwinds in 2025 including tariffs, weaker China demand, funding disruptions in US academia, delayed customer capital spending, while pursuing cost-out actions to support a margin rebound.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bruker Corporation published the original content used to generate this news brief on April 10, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.